Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects

NCT00607373 is registered in ClinicalTrials.gov with Kastle Therapeutics, LLC as lead sponsor.

NCT NCT00607373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00607373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects
Lead sponsor
Kastle Therapeutics, LLC
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2007
Completion date
March 31, 2009
Enrollment
51 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

congenital abnormalities, dyslipidemias, genetic diseases, inborn, hypercholesterolemia, hypercholesterolemia, autosomal dominant, hyperlipidemias, hyperlipoproteinemia type ii, hyperlipoproteinemias, infant, newborn, diseases, lipid metabolism disorders, lipid metabolism, inborn errors, metabolic diseases, metabolic disorder, metabolism, inborn errors